Corbus Pharmaceuticals
Committed to leveraging expertise in immunology to fulfill purpose of developing innovative new medicines
Norwood, United States
50 employees
Post-IPO Equity
Total: $341.45M
Biotechnology, Pharmaceutical
General Information
Norwood, United States
BounceWatch is an independent company data service, not affiliated with Corbus Pharmaceuticals. To contact Corbus Pharmaceuticals, visit corbuspharma.com.
Is this your company?
Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.
Get Verified
How does Corbus Pharmaceuticals compare?
A PDF of Corbus Pharmaceuticals and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.
This takes a few seconds: we look beyond our own index too.
Meeting Corbus Pharmaceuticals soon?
A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample
Discover More
United States Market
Biotechnology
About Corbus Pharmaceuticals
Business keywords: Precision oncology, Cancer immunotherapy, Antibody drug conjugate, TGFβ inhibition, Endocannabinoid system, CB2 agonist, Inflammatory diseases, Fibrotic diseases, Lenabasum, Fibrosis resolution, Systemic sclerosis, Cystic fibrosis, Dermatomyositis, NASH, Phase 3 clinical-stage pharmaceutical company
Funding Rounds & Investors (12)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Post IPO Equity | $94.50M | - |
|
31 Jan 2024 |
| Post IPO Debt | $50.00M | 1 |
|
28 Jul 2020 |
| Post IPO Equity | $46.00M | - |
|
06 Feb 2020 |
| Post IPO Equity | $40.00M | - |
|
24 Jan 2019 |
| Grant | $25.00M | - |
|
30 Jan 2018 |
| Post IPO Equity | $27.10M | - |
|
28 Feb 2017 |
| Post IPO Equity | $14.80M | 3 |
|
10 Jun 2016 |
| Grant | $5.00M | 1 |
|
22 Apr 2015 |
| Post IPO Equity | $12.75M | - |
|
08 Dec 2014 |
| Venture Round | $6.30M | 2 |
|
28 Apr 2014 |
Corbus Pharmaceuticals Alternatives & Competitors
View All Alternatives
Creating Transformative Immunotherapies for Patients with Cancer
Developing innovative therapeutics for diseases at confluence of fibrosis and inflammation with high...
Biotech company focusing on the discovery and development of novel targeted medicines to treat cance...
FAQ About Corbus Pharmaceuticals
Source: BounceWatch company record for Corbus Pharmaceuticals, https://bouncewatch.com/company/corbus-pharmaceuticals, updated 30 December 2024. When citing, please name BounceWatch and link this page.
